Sign In
Free Newsletter
May 12, 2026
Bristol Myers Squibb inks $15.2B drug deal with Hengrui
The partnership with Hengrui Pharma will develop 13 oncology, hematology and immunology drug programs worldwide.
Jan 8, 2024
Merck’s $680M Harpoon acquisition to diversify oncology pipeline
According to Dr. Dean Li, president, Merck Research Laboratories, “This agreement reflects the creativity and commitment of scientists and clinical development teams at Harpoon," a South San Francisco-based clinical-stage immunotherapy company.
